Imaging Technologies, Expert Perspectives, Standardization, and Current Outlooks

NEEDHAM, MASSACHUSETTS, UNITED STATES, May 21, 2014 /EINPresswire.com/ -- NEEDHAM, MASS. – Insight Pharma Reports, a scientific report leader for over 15 years, announces the release a new research report: Digital Pathology Insights: Imaging Technologies, Expert Perspectives, Standardization, and Current Outlooks.

Just released, this report delves into the rapidly evolving field of digital pathology, briefly reviewing the underlying scientific and technological concepts and providing an insightful perspective on various factors thought to be of significance to the development and future of this space.

A brief overview of the digital pathology market will cover identified drivers and obstacles as well as current forecasts. The FDA and several standards organizations are profiled with regard to activities that may impact the furtherance of this field. Included in this section is an exclusive interview with Craig Revie, Chair of the International Color Consortium’s Medical Imaging Working Group and project coordinator for the development of a calibration system for digital microscopes.

Companies featured in this report include; 3DHISTECH, Applied Spectral Imaging, Carl Zeiss Microscopy GmbH, DigiPath Corp, FFEI Ltd., Huron Technologies, Nikon Instruments, PerkinElmer and Philips Digital Pathology Solutions. These companies have provided valuable insights as to the evolution of digital pathology within their businesses, the details of their current imaging systems, strategies, and techniques, as well as their individual perspectives on the establishment of standards in digital pathology, the challenges the field may face and the benefits that await as a digital environment becomes commonplace in pathology. Interviews with the expert company representatives are also included.

Finally, the report concludes with a unique look at the current climate of the digital pathology space based on a survey conducted by Insight Pharma Reports which polled a group of individuals identified as end users or developers of digital pathology technologies. An in depth analysis of these results compares the perspectives of both demographics on several important topics revealing areas of commonality and also divergence. Topics include areas most in need of improvement and the challenges and benefits associated with the use and development of digital pathology technologies.

For more information and to purchase this Insight Pharma Report, visit: http://www.insightpharmareports.com/digitalpathology or contact Kerri Kelley at kkelley@InsightPharmaReports.com or 781-972-1347.

About Insight Pharma Reports
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute. http://www.InsightPharmaReports.com

Insight Pharma Reports offers our Affiliated Reports Collection which provides a repository of additional scientific and business resources. For more information, visit http://www.insightpharmareports.com/affiliatedreports/

Kerri Simpson
Cambridge Healthtech Institute
7819721347
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.